Given the promising outcomes of inhibiting IL-1 in suppressing breast cancer bone metastasis, we have evaluated the effects of small molecule inhibitors that target different parts of the IL1β signalling pathway (Caspase-1, IL1β and IRAK1, Interleukin 1 Receptor Associated Kinase 1) on breast cancer bone metastasis. Here, IRAK1 is linked to breast cancer.